Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Part B Demo Could Save $2.2 Bil., CBO Says; Blocking It Would Cost Less

Executive Summary

CMS’ proposal to test alternate payment methods for Part B drugs could save as much as $2.2 billion over 10 years, the Congressional Budget Office told Congress. However, a bill to block implementation of the program would only cost $395 million for scoring purposes.


Related Content

Trump’s ACA Repeal: What’s In It For Biopharma?
Trump’s ACA Repeal: What’s In It For Biopharma?
Drug Pricing: With "Value" Debate In Full Swing, ICER’s Influence Grows
340B Impact: Roche Starts Educating Investors About Discount
Clinton Transition Co-Chair Tanden Offers Themes For A Drug Pricing Bill In 2017
Medicare Part B Demo Partially Shielded From Congress By CBO Scoring
Part B Demo Comments Overwhelmingly Negative, Uniform In Content
Thinking Outside The Box On Rx Pricing: From Vaccines To Part D Bundling